What’s Next? Five Things To Look Out For In November
Another Avastin Biosimilar Could Be Approved In US
In November, ANI Pharmaceuticals is hoping to complete a major acquisition, Viatris may shed further light on the state of the US generics industry and Generics Bulletin will host its eighth annual Global Generics & Biosimilars Awards, this year once again in person.
You may also be interested in...
Teva faced questions about the current environment in the US for generics, following weakness in its numbers and in those of rival Sandoz during the third quarter. Management remains “very committed to the US generics segment,” after sales dropped by 7%.
Analysts in Q3 pounced on a quirk in the complex US healthcare system that has provided small relief to Biogen’s much-depleted Tecfidera franchise in the US in the face of many generic rivals.
Celltrion has indicated that it intends to leverage its ability to compete on cost to gain a foothold in the bevacizumab market, despite being a “latecomer” in the wake of firms that have previously launched and filed biosimilar rivals to Avastin.